Literature DB >> 3419289

Changes of serum HBV-DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis.

Y F Liaw1, C C Pao, C M Chu.   

Abstract

To examine the relationship between changes of serum hepatitis B virus-dexoyribonucleic acid (HBV-DNA) and transaminase levels during acute exacerbation of chronic type B hepatitis, serial serum specimens from 74 patients were assayed for HBV-DNA by slot blot hybridization with 32P-labeled cloned HBV-DNA as probe. Of these patients, serial serum specimens were obtained with an interval of 2-7 days in 22 patients (Group I), 8-14 days in 30 patients (Group II) and 15-30 days in 22 patients (Group III). The peak of serum HBV-DNA was reached shortly before or simultaneously with the maximum elevation of serum alanine transaminase (ALT) in most (greater than 90%) of the acute exacerbations. In contrast, the peak of serum ALT was reached before maximum elevation of serum HBV-DNA in only 13.6% of Group I, 3.3% of Group II and 13.6% of Group III (9.5% of whole series). The results suggest that the increase of serum HBV-DNA is an event preceding, rather than the result of, hepatocytolysis in most of the acute exacerbations occurring in patients with chronic type B hepatitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3419289     DOI: 10.1111/j.1600-0676.1988.tb00998.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  9 in total

1.  Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis.

Authors:  C M Chu; C T Yeh; Y F Liaw
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

2.  Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic.

Authors:  C M Chu; C T Yeh; C T Chiu; I S Sheen; Y F Liaw
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

3.  Detection of hepatitis B virus DNA in serum using synthetic non-radioactive oligonucleotides.

Authors:  A Manzin; P Pauri; P Bagnarelli; F Brecciaroli; P E Varaldo; S Colloca; M Clementi
Journal:  J Clin Pathol       Date:  1989-11       Impact factor: 3.411

4.  Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis B.

Authors:  T Laskus; J Rakela; M J Tong; D H Persing
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

Review 5.  Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection.

Authors:  Yun-Fan Liaw
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-09-02       Impact factor: 46.802

Review 6.  The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde.

Authors:  Zina Valaydon; Marc Pellegrini; Alexander Thompson; Paul Desmond; Peter Revill; Gregor Ebert
Journal:  Clin Transl Immunology       Date:  2016-12-09

Review 7.  Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation.

Authors:  Wei-Lun Tsai; Wei-Chi Sun; Jin-Shiung Cheng
Journal:  Int J Mol Sci       Date:  2015-11-26       Impact factor: 5.923

8.  Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China.

Authors:  Fang Lei; Ye-Mao Liu; Feng Zhou; Juan-Juan Qin; Lihua Zhu; Peng Zhang; Xiao-Jing Zhang; Jingjing Cai; Lijin Lin; Shan Ouyang; Xiaoming Wang; Chengzhang Yang; Xu Cheng; Weifang Liu; Haomiao Li; Jing Xie; Bin Wu; Huiming Luo; Fei Xiao; Jing Chen; Liang Tao; Gang Cheng; Zhi-Gang She; Jianghua Zhou; Haitao Wang; Jun Lin; Pengcheng Luo; Shouzhi Fu; Jihui Zhou; Ping Ye; Bing Xiao; Weiming Mao; Liming Liu; Youqin Yan; Ling Liu; Guohua Chen; Hongliang Li; Xiaodong Huang; Bing-Hong Zhang; Yufeng Yuan
Journal:  Hepatology       Date:  2020-08       Impact factor: 17.298

Review 9.  Severe Guillain-Barré syndrome associated with chronic hepatitis B: A case report and literature review.

Authors:  Jiajun Wei; Shenhan Duan
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.